Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Income from Continuing Operations (2016 - 2025)

Ultragenyx Pharmaceutical has reported Income from Continuing Operations over the past 10 years, most recently at 128556000.0 for Q4 2025.

  • Quarterly Income from Continuing Operations rose 4.21% to 128556000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 575000000.0 through Dec 2025, down 0.88% year-over-year, with the annual reading at 575000000.0 for FY2025, 0.88% down from the prior year.
  • Income from Continuing Operations was 128556000.0 for Q4 2025 at Ultragenyx Pharmaceutical, up from 180413000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 485449000.0 in Q4 2023 and troughed at 245106000.0 in Q3 2022.
  • The 5-year median for Income from Continuing Operations is 143610500.0 (2021), against an average of 92538600.0.
  • The largest YoY upside for Income from Continuing Operations was 1284.5% in 2021 against a maximum downside of 583.62% in 2021.
  • A 5-year view of Income from Continuing Operations shows it stood at 332856000.0 in 2021, then crashed by 146.11% to 153473000.0 in 2022, then surged by 416.31% to 485449000.0 in 2023, then crashed by 127.64% to 134202000.0 in 2024, then increased by 4.21% to 128556000.0 in 2025.
  • Per Business Quant, the three most recent readings for RARE's Income from Continuing Operations are 128556000.0 (Q4 2025), 180413000.0 (Q3 2025), and 114951000.0 (Q2 2025).